Group 1 - President Trump announced an executive order aimed at reducing prescription drug prices in the U.S. by 30% to 80%, claiming U.S. prices are significantly higher than in other countries [1][2] - The proposed "most favored nations' policy" would align U.S. drug prices with the lowest prices paid globally, potentially leading to immediate price cuts for consumers [2][7] - Shares of major pharmaceutical companies, including J&J, Eli Lilly, and Pfizer, declined in pre-market trading following the announcement, indicating market concern over the impact of the order [2][3] Group 2 - The U.S. government has been attempting to control healthcare costs through the Inflation Reduction Act, which allows Medicare to negotiate drug prices directly with manufacturers, a significant shift from previous regulations [4][5] - The Medicare price negotiation program is set to redesign the Part D program, imposing more liability on drugmakers and introducing penalties for significant price increases [5][6] - The list of drugs eligible for negotiation primarily includes high-cost medications for serious conditions, which represent a substantial portion of Medicare spending [6][7] Group 3 - The implementation of the "most favored nations' policy" is expected to save the government trillions of dollars but could severely impact the sales and profits of large drug manufacturers [7] - The global pharmaceutical industry is anticipating further details on the executive order, as the announcement did not clarify its applicability to Medicare, Medicaid, or other government health programs [7]